TABLE 1.

Characteristics of the included patients and plasma CMS and formed colistin concentrations

Patient	Gender	Age (yr)	CMS daily dose (MIU/h)	SCra (mg/liter)		eGFRa,b (ml/min)		Cmin ss/Cmax ss (mg/liter)c		AKI (RIFLE classification)d	Other nephrotoxic drugsd
				Initial	Final	Initial	Final	Formed colistin in plasma	CMS in plasma
1	Female	72	1/24	5.18	6.25	9	7	0.8/0.8	1.9/4.5	N	Y (furosemide)
2	Male	57	1/8	0.36	0.57	266	156	NA/1.5	5.9/11.7	Y (R)	Y (furosemide)
3	Male	44	1/8	1.45	1.4	56	2	0.4/0.6	1.7/4.7	N	N
4	Male	67	2/12	1.51	1.36	49	56	0.9/0.9	4.1/9.3	N	Y (furosemide, NSAIDs)
5	Male	63	2/8	0.95	0.77	85	108	1.4/NA	4.2/NA	N	Y (furosemide, vancomycin)
6	Male	70	2/8	0.86	1.89	93	38	0.8/NA	1.6/NA	Y (I)	Y (furosemide, vancomycin, NSAIDs, ACE inhibitor)
7	Male	65	3/8	0.47	0.19	190	332	0.7/0.7	2.2/11.4	N	Y (furosemide, NSAIDs)
8	Female	63	3/8	0.53	1.02	122	58	0.9/0.9	5.9/11.7	Y (I)	Y (amikacin)
9	Male	84	4.5/12	0.6	0.7	136	114	1.4/1.4	4.6/19.8	N	Y (furosemide, vancomycin)
10	Female	86	2/8	0.68	0.59	116	103	1.3/1.3	2.7/9.6	N	Y (furosemide)
11	Male	66	2/12	1.47	1.52	51	49	NA/0.7	NA/9.0	N	Y (furosemide)
12	Male	37	2/8	0.4	0.48	257.3	208.5	<0.2/<0.2	NA	N	Y (NSAIDs)

^aInitial and final CMS treatments. SCr, serum creatinine; eGFR, estimated glomerular filtration rate; AKI, acute kidney injury.

^bMDRD-4 equation.

^cNA, not available.

^dY, yes; N, no; R, risk stage; I, injury stage.